<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:464272430;
mso-list-template-ids:-510363766;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1
{mso-list-id:666785726;
mso-list-template-ids:-1689746144;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2
{mso-list-id:1038748538;
mso-list-template-ids:295188282;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3
{mso-list-id:1889753635;
mso-list-template-ids:1922463582;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l3:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="http://www.whitehall.org/grants/" target="_blank">Whitehall Foundation Grant Programs</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">It is the Whitehall Foundation’s policy to assist those dynamic areas of basic biological research that are not heavily supported by federal agencies or other foundations with specialized
missions. The Whitehall Foundation is currently interested in basic research in neurobiology, defined as follows: <b>Invertebrate and vertebrate (excluding clinical) neurobiology, specifically investigations of neural mechanisms involved in sensory, motor,
and other complex functions of the whole organism as these relate to behavior. The overall goal should be to better understand behavioral output or brain mechanisms of behavior.
</b>The Whitehall Foundation does not support research focused primarily on disease(s) unless it will also provide insights into normal functioning.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Research Grants</span></b><span style="font-size:12.0pt;font-family:Palatino"><br>
Research grants are available to established scientists of all ages working at accredited institutions in the United States. Applications will be judged on the scientific merit and the innovative aspects of the proposal as well as on the competence of the applicant.
Research grants of up to three years will be provided. A renewal grant with a maximum of two years is possible, but it will be awarded on a competitive basis. Research grants will not be awarded to investigators who have already received, or expect to receive,
substantial support from other sources, even if it is for an unrelated purpose. Research grants normally range from $30,000 to $75,000 per year.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Grants-in-Aid</span></b><span style="font-size:12.0pt;font-family:Palatino"><br>
The Grants-in-Aid program is designed for researchers at the assistant professor level who experience difficulty in competing for research funds because they have not yet become firmly established. Grants-in-Aid can also be made to senior scientists. All applications
will be judged on the scientific merit and innovative aspects of the proposal, as well as on past performance and evidence of the applicant’s continued productivity. Grants-in-Aid are awarded for a one-year period and do not exceed $30,000.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Letter of intent due January 15, 2022; April 15, 2022; and October 1, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for January 15, 2022 due date: January 3.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=336610">National Institute of Standards and Technology: Precision Measurement Grant Program (PMGP)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The PMGP is seeking applications to support significant research in the field of fundamental measurement or the determination of fundamental constants. See
<a href="https://www.nist.gov/laboratories/projects-programs?k=&a%5B%5D=248321&tag=">
Bioscience Topic Area</a> for examples of projects/programs of interest.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Abbreviated applications (~5 double spaced pages) due February 4, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: January 24.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-047.html" target="_blank">Alzheimer’s Drug-Development Program (U01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic
drug candidates that prevent Alzheimer’s disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics
(PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I
clinical testing. Applications not responsive to this FOA include: research on basic mechanisms of disease or mechanisms of drug action; development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed
drugs and combinations therapies; discovery activities such as high-throughput screening and hit optimization; and stand-alone clinical trials.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires November 6, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for February 5, 2022 standard date: January 25.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Drug Discovery For Nervous System Disorders (R21 / R01 Clinical Trials Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-032.html" target="_blank">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-031.html" target="_blank">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">These Funding Opportunity Announcements (FOAs) support the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through these FOAs NIMH, NIA, NIAAA
and NIDA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of
interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic
agents.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires January 8, 2025.
<span style="color:red">Med-RA deadline to receive draft documents for February 5, 2022 R01 standard date: January 25; February 16, 2022 R21 standard date: February 3.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grantsandgiving.biogen.com/content/gma-grants-office/en/us/grants.html">Biogen Medical Education, Patient Education, and Professional & Scientific Development Grants</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Biogen considers requests across a variety of disease areas including:<br>
Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Lupus, Multiple Sclerosis, Ophthalmology, Parkinson’s Disease, and Spinal Muscular Atrophy.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Medical Education</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Funding to an eligible institution or organization to support independent medical educational activities for HCPs and researchers. Medical education may be accredited or non-accredited.
Current areas of interest: Alzheimer’s disease and multiple sclerosis.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Patient and Caregiver Education</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Funding to an eligible institution or organization to support independent educational activities for patients or caregivers. Current areas of interest: Alzheimer’s disease, multiple sclerosis,
and spinal muscular atrophy.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">General Grants</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Funding to support a project or program that does not fit any of the other defined grant categories. Current areas of interest: Alzheimer’s disease, multiple sclerosis, and spinal muscular
atrophy.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 15, 2022; May 15, 2022; August 15, 2022; and November 1, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for February 15, 2022 due date: February 2.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.nsf.gov/pubs/2022/nsf22526/nsf22526.htm">NSF: Ethical and Responsible Research (ER2)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The program encourages research that supports and extends our understanding of how and why research approaches, practices, and norms foster or hinder the training of STEM researchers and
practitioners. The program aims to support the formation, reproduction, and dissemination of ethical academic and research practices and to cultivate institutional cultures that value, expect, and reward academic and research integrity (NASEM 2016, NASEM 2017,
NASEM 2019). Ethical issues in emerging scientific and technological areas are of particular interest as are new ethical issues created by changing cultural norms. Those topics include, but are not limited to:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">environmental change, climate mitigation and adaptation research<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">artificial intelligence and robotics<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">sensor data and other digital representations of human experiences<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">quantum research<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">bioeconomy ecosystems: society and biotechnology<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">advanced communications technologies<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">equity and inclusion in STEM research<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">the prevention of sexual harassment in STEM<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">the ethical norms of indigenous and international STEM research.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The program ultimately aims to increase the number of students, postdoctoral fellows, and faculty members exposed to multiple levels and dimensions of responsible conduct of research (Herkert,
J.R. 2004). The program also seeks to motivate, inform, and educate students and faculty to explore and be cognizant of the ethical dimensions of STEM to ensure responsible and ethical conduct of research that is responsive to the needs, values, and norms
of society.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 17, 2022 and January 23, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for February 17, 2022 due date: February 7.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-036.html">NIH HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants
(R01 Clinical Trials Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">In April 2018, the National Institutes of Health (NIH) launched the
<a href="http://www.nih.gov/research-training/medical-research-initiatives/heal-initiative">
Helping to End Addiction Long-term<sup>SM</sup>Initiative or HEAL Initiative<sup>SM</sup></a>, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. Through this initiative the National Institute
on Drug Abuse, in partnership with other NIH Institutes, Centers, and Offices, requests applications for studies designed to develop and test multi-level interventions to prevent opioid misuse, opioid use disorder, and co-occurring conditions by intervening
on social determinants of health. This initiative aims to build an evidence base for multi-level interventions that target malleable factors and conditions affecting the social context. Applications must seek to reduce health inequities in a U.S. population
or population subgroup affected by the opioid crisis by studying the effects of a theory driven, multi-level intervention on the prevention of opioid misuse/opioid use disorder and co-occurring conditions. Such conditions could include mental health conditions
and/or suicide, and may also include other substance use and substance use-related outcomes. The research project must examine the mechanisms by which the interventions exert their effects, and conduct economic analyses to inform decisions about adoption of
strategies. Investigators should study interventions that are sustainable and easily taken to scale if effective.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 2, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: February 17.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-22-001.html">Supporting Talented Early Career Researchers in Genomics (R01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement is intended to identify and support research projects by exceptionally promising Early Stage Investigators with a long-term career interest in pursuing
innovative research in genomics. This opportunity is open to research in all areas relevant to the mission of NHGRI, including genomic sciences, genomic medicine, genomic data science, and ethical, legal, and social implications of genomics.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 4, 2022; February 28, 2023; and February 27, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for March 4, 2022 due date: February 21.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-055.html" target="_blank">Data Harmonization, Curation and Secondary Analysis of Existing Clinical Datasets (R61 / R33 Clinical
Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This funding opportunity announcement invites applications from multidisciplinary teams to perform secondary data analysis, using existing datasets from two or more multi-site clinical
research projects, including clinical trials, natural history studies, and/or comparative effectiveness research. Secondary analyses should address scientific and / or clinical hypotheses that can advance the understanding or care of neurological disorders
and conditions within the NINDS mission. In this phased award funding mechanism, applications are required to systematically and comprehensively perform cross-project data harmonization and curation, assessed using go/no-go data-quality metrics, prior to performing
secondary analyses of existing clinical data. Consistent with the FAIR (findable, accessible, interoperable and reusable) data principles, this funding opportunity expects open-source cataloging of the processes and tools used for harmonization, curation,
and analysis, as well as controlled access to the curated datasets.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 15, 2022; March 14, 2023; and March 14, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for March 15, 2022 due date: March 2.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-071.html" target="_blank">Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement is designed to enable the translation of nanotechnology-based cancer interventions relying on nanoparticle formulations and/or nano-devices. The TTNCI
initiative encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are expected to mature experimental nanomedicines designed for highly relevant cancer clinical
objectives with a strong potential to improve cancer treatment effectiveness. It is expected that improvement of treatment effectiveness will occur due to the combination of nanoparticle/nano-device structural design and/or therapeutic/diagnostic cargo which
is delivered. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational
programs.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due May 17, 2022; November 17, 2022; May 17, 2023; November 17, 2023; May 17, 2024; and November 17, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for May 17, 2022 due date: May 4.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-069.html" target="_blank">High impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of the High Impact, Interdisciplinary Science grants program is to support high impact ideas that may lay the foundation for new fields of investigation within the mission
of NIDDK. The interdisciplinary approach encouraged by this FOA is envisioned to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community. This FOA seeks
novel approaches in areas that address specific knowledge gaps, scientific opportunities, new technologies, data generation, or research methods that will advance the area in significant ways designed to accelerate scientific progress in the understanding,
treatment, and prevention of diseases within the mission of the NIDDK.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due June 1, 2022; November 2, 2022; June 1, 2023; November 2, 2023; May 30, 2024; and October 30, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for June 1, 2022 due date: May 18 (due to Memorial Day holiday).</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-030.html" target="_blank">New Investigator Gateway Awards for Collaborative T1D Research (R03 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The New Investigator Gateway Award in T1D Research is designed to support a robust pipeline of innovative projects and talented new investigators in T1D research. In addition to providing
support for preliminary research, the Gateway program provides an opportunity for new Program Directors/Principal Investigators (PD/PIs) to pursue their studies within the intellectual environment of a select number of large, ongoing collaborative research
programs. Embedding awardees within an established scientific framework in each of these consortia will provide unique opportunities for New and Early Stage Investigators to increase their understanding of key questions in the field, to network, and to establish
unique and potentially long-lasting collaborations that will propel their careers forward. Bringing New and Early Stage Investigators into existing collaborative research networks will also benefit the networks by providing new ideas and perspectives.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due June 1, 2022 and March 20, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for June 1, 2022 due date: May 18 (due to Memorial Day holiday).</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-22-006.html">Expert-Driven Small Projects to Strengthen Gabriella Miller Kids First Discovery (R03 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) with the vision of alleviating suffering from childhood cancer and structural
birth defects by fostering collaborative research to uncover the etiology of these diseases and supporting data sharing within the pediatric research community. Kids First has established and continues to develop a Data Resource including a large collection
of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. This FOA is intended to engage experts in a variety of activities
that will enhance the utility of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets and resources. These activities should strengthen future analyses of Kids First datasets
by the broader researcher community with the ultimate goal of improving diagnostic capabilities and therapies for children and their families affected by these conditions.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due June 10, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: May 31.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.bwfund.org/wp-content/uploads/2021/09/BWF_CCHH_RFP_v4.pdf">Burroughs Wellcome Fund: Climate Change and Human Health</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Burroughs Wellcome Fund aims to stimulate the growth of new connections between scholars working in largely disconnected fields who might together change the course of climate change’s
impact on human health. Over the next two years, we will dedicate $1M to supporting small, early-stage grants of $2,500 – $50,000 toward achieving this goal.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Proposals accepted on a rolling basis through August 30, 2023</span></b><span style="font-size:12.0pt;font-family:Palatino">.
<b><span style="color:red">Med-RA deadline to receive draft documents: Ten business days before submission to sponsor.</span></b><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.nsf.gov/pubs/2022/nsf22015/nsf22015.jsp?WT.mc_ev=click&WT.mc_id=USNSF_26&utm_medium=email&utm_source=govdelivery">Dear Colleague Letter: NSF-DFG (Deutsche Forschungsgemeinschaft,
German Research Foundation) Lead Agency Opportunity in Molecular and Cellular Biology</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">To facilitate the support of collaborative work between US researchers and their German counterparts, the
<i>Division of Molecular and Cellular Bioscience (BIO/MCB)</i> at NSF and the Division of Molecular and Organismal Biology and Agriculture (MOBA) at DFG are pleased to announce a Lead Agency Opportunity in the area of Molecular and Cell Biology (NSF-DFG MolCellBio).
The goal of this Opportunity is to help reduce some of the current barriers to working internationally. This Lead Agency Opportunity allows US and German researchers to develop and submit a single proposal to either NSF or DFG describing a project involving
US and German researchers that will undergo a single review process by the designated Lead Agency. US and German collaborators are invited to submit joint proposals in the areas covered by NSF's BIO/MCB and DFG's review board 201 "Basic Research in Biology
and Medicine." The proposals should focus on basic research at a molecular, subcellular or cellular level, including theoretical approaches. Proposals encompassing tissues, organs or whole animals will not be considered. Research in the areas of plant sciences,
microbiology, immunology, and neurosciences is also excluded. Proposals must provide a clear rationale for the need for a US-German collaboration, including the unique expertise and synergy that the collaborating researchers will bring to the project. Proposers
should note that this Lead Agency Opportunity does not represent new or ring-fenced funding. Researchers in Germany are invited to read the Information for Researchers to be posted under
<a href="https://www.nsf.gov/cgi-bin/good-bye?https://www.dfg.de/en/research_funding/international_cooperation/funding/countries_regions/index.html#anker106258056">
Funding Opportunities with Individual Countries</a> for more information.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Proposals accepted any time.
<span style="color:red">Med-RA deadline to receive draft documents: Ten business days before submission to sponsor.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.nsf.gov/pubs/2022/nsf22016/nsf22016.jsp?WT.mc_ev=click&WT.mc_id=USNSF_26&utm_medium=email&utm_source=govdelivery">Dear Colleague Letter: Organismal Systems and Infection
Biology (OSIB)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">With this Dear Colleague Letter (DCL) the Division of Integrative and Organismal Systems (IOS) is calling for proposals that build on our ongoing programs to move forward our understanding
of infection processes in natural systems. All study systems are appropriate, except those that focus solely on human diseases. Proposals that focus on building a mechanistic understanding are encouraged. Comparative approaches to the study of immune systems,
in a phylogenetic context, are also encouraged; these studies are expected to discover conserved and convergent immune responses or cell types. Proposals that focus on interactions between immune responses and other physiological, developmental, neural and
behavioral phenotypes are well suited to this call. Below are some examples; they are not intended to constitute a comprehensive list.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Examples include<o:p></o:p></span></b></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Investigation of interspecific variation in host responses to infection across a clade<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Evolutionary history of immune mechanisms and function, or immune cell or system diversity, including origins of individual immune system components<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Parental effects and interactions or social and/or environmental experiences that determine infection outcomes<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Behaviors responsible for, or manipulated by, infectious agent(s)<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Infection effects on the neural-immune system with consequences for development, neural function in adults, and organismal behavior<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Developmental transitions during an organism’s lifespan and the interplay between immune system components and physiological processes<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Systems biology approaches to understand integrated organismal immunity and how immunity maps from genotype-to-immune phenotypes<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">In addition to research proposals, we invite Workshop/Conference proposals to foster new research directions in these areas, as well as proposals for Research Coordination Networks (RCNs)
that would bring together disparate data to generate new insights and new research directions.
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Research proposals should be submitted to the IOS program most-closely related to the proposed activities through the
<a href="https://beta.nsf.gov/funding/opportunities/division-integrative-organismal-systems-core-programs-ios">
IOS Core Programs solicitation</a> (NSF 21-506), the <a href="https://beta.nsf.gov/funding/opportunities/plant-biotic-interactions">
Plant-Biotic Interactions</a> (NSF 20-576), the <a href="https://beta.nsf.gov/funding/opportunities/plant-genome-research-program-pgrp">
Plant Genome Research Program</a> (NSF 21-507), or the <a href="https://beta.nsf.gov/funding/opportunities/enabling-discovery-through-genomics-edge">
Enabling Discovery through Genomics</a> (NSF 21-546) solicitation. Proposals for <a href="https://beta.nsf.gov/funding/opportunities/research-coordination-networks">
Research Coordination Networks</a> (RCN) should be prepared and submitted consistent with the guidelines in the RCN solicitation. Proposals for conferences must be prepared and submitted in accordance with the guidance for Conference Proposals contained in
Chapter II.E.9 of the NSF Proposal and Award Policies and Procedures Guide (PAPPG). In addition to any solicitation or PAPPG specific requirements, titles should start with "OSIB:". Researchers are strongly encouraged to consult with IOS Program Directors
in the IOS program most closely related to the proposed activities as determined by the primary questions being asked and the hypotheses being tested prior to submitting a proposal.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Deadlines vary by program. IOS Core Programs accepts proposals any time. Enabling Discovery through Genomics deadline is February 17, 2022 (third Thursday in February annually thereafter).
<span style="color:red">Med-RA deadline to receive draft documents: Ten business days before submission to sponsor.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">To search for additional funding opportunities, please visit <a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69">CoM’s
unofficial funding opportunities blog</a>.<o:p></o:p></span></b></p>
</div>
</body>
</html>